MENUMENU
  • About Us
    • Statement From CEO
    • Our Leadership
    • Partnerships
  • Programs
    • Personal Cancer Immunotherapy
    • The Clean Super Vaccine
    • Publications
  • News & Media
  • Contact Us
    • Contact Us
    • Careers
MENUMENU
  • About Us
    • Statement From CEO
    • Our Leadership
    • Partnerships
  • Programs
    • Personal Cancer Immunotherapy
    • The Clean Super Vaccine
    • Publications
  • News & Media
  • Contact Us
    • Contact Us
    • Careers
  •  
  • Uncategorized

AIVITA Biomedical Announces Publication Detailing 50% Enhanced Survival in Phase 2 GBM Study

AIVITA Biomedical CEO Dr. Hans Keirstead Wins Innovator of the Year Award

AIVITA Biomedical CEO Dr. Hans Keirstead to Deliver Keynote Address at United Nations ‘AI for Good’ Meeting

AIVITA Biomedical Announces Publication of Phase 1 and Phase 2 Trial Results of its COVID-19 Vaccine Candidate

AIVITA Biomedical Appoints Dr. H. Christian Fibiger to its Board of Directors

AIVITA Biomedical CEO Dr. Hans Keirstead to Deliver Keynote at Festival of Biologics

AIVITA Biomedical CEO Dr. Hans Keirstead to Deliver Keynote At Vaccine World Asia Congress

AIVITA Biomedical CEO Dr. Hans Keirstead to Chair Keynote Panel and Deliver Talk at World Immunotherapy Congress Europe

AIVITA Biomedical’s Stem Cell-Derived Retina Transplant Restores Vision Loss in Preclinical Study

AIVITA Biomedical CEO Dr. Hans Keirstead to Give Keynote Address at Advanced Therapies Congress in London

  • Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next

AIVITA Biomedical is a biotechnology company developing personalized vaccines that target infectious diseases and tumor-initiating cells — the seed of all cancers — using our autologous cell platform. We leverage our unique expertise in stem cell growth and directed, high-purity differentiation to develop safe, efficient and economical manufacturing processes for therapeutic development in cancer, infectious disease and other fields.

Recent News

  • AIVITA Biomedical Strengthens Board of Directors with Appointment of Global Health and Vaccine Readiness Leader Larry Brilliant
  • AIVITA Biomedical Nominated for 2026 Prix Galien USA Award
  • AIVITA Biomedical Licenses Novel Skincare Formulations to Global Skincare Retailer LevEllis
  • AIVITA Biomedical CEO Dr. Hans Keirstead and CMO Dr. Robert Dillman to Speak and Participate in Keynote Panel at Festival of Biologics USA
  • AIVITA Biomedical CEO Dr. Hans Keirstead to Join Keynote Panel for AI in Public Health at World Vaccine Congress

Site Navigation

  • About Us
  • Programs
  • News & Media
  • Contact Us
Copyright © 2023 | AIVITA Biomedical, Inc.